7 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow fedratinib: new trials by email Literature Review of fedratinib trials Research Report on fedratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Fedratinib in Combination With Nivolumab Fedratinib Oral Capsule [Inrebic], Nivolumab - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 30 | 2022-06-14 | 2026-04-08 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Fedratinib Pill - Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2022-03-01 | 2026-06-09 |
| A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) BMS-986158, Ruxolitinib, Fedratinib - Myelofibrosis | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 216 | 2021-03-22 | 2026-05-08 |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Cyclophosphamide, JAK Inhibitor, Fludarabine - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2021-02-09 | 2026-07-20 |
| A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Fedratinib - Primary Myelofibrosis | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 31 | 2020-10-12 | 2026-11-12 |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Recruiting | University of Washington | 25 | 2020-03-24 | 2026-09-17 |
| Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly SAR302503 - Myelofibrosis | Phase 2 | Completed | Bristol-Myers Squibb | 8 | 2012-11-01 | 2025-03-05 |
| Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib SAR302503 - Hematopoietic Neoplasm | Phase 2 | Terminated | Bristol-Myers Squibb | 97 | 2012-04-30 | 2026-07-16 |
| Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia SAR302503 - Hematopoietic Neoplasm | Phase 2 | Completed | Bristol-Myers Squibb | 81 | 2011-10-01 | 2025-03-05 |
| Phase 2 Study of SAR302503 in Patients With Myelofibrosis SAR302503 - Hematopoietic Neoplasm | Phase 2 | Completed | Bristol-Myers Squibb | 30 | 2011-08-01 | 2025-03-05 |
| A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis SAR302503 (TG101348) - Myelofibrosis | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 43 | 2008-07-31 | 2026-10-06 |
Primary Myelofibrosis (8) · Hematologic Neoplasms (3) · Myeloproliferative Disorders (2) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Neutrophilic, Chronic (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
Bristol-Myers Squibb (7) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · John Mascarenhas (1) · University of Washington (1)
United States (9) · Germany (4) · France (3) · Italy (3) · Spain (3) · Australia (2) · Canada (2) · Japan (2) · South Korea (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Greece (1) · Israel (1) · Netherlands (1)
Andrew Kuykendall, MD (1) · Anna Halpern (1) · Anthony M Hunter, MD (1) · Ayalew Tefferi, MD (1) · John Mascarenhas, MD (1) · Rachel B. Salit (1) · Salah-Eddin Al-Batran, Prof. Dr. (1)
2023 (1), P01CA108671 (1)